Combination immunotherapy for pancreatic cancer: challenges and future considerations

Area of Science:

• Oncology
• Immunology
• Cancer Research

Background:

• Pancreatic ductal adenocarcinoma (PDA) exhibits limited response to immune checkpoint inhibitors (ICI).
• The tumor microenvironment (TME) in PDA is characterized by immunosuppressive factors hindering effective anti-tumor immunity.
• Understanding these resistance mechanisms is crucial for developing novel therapeutic strategies.

Approach:

• Reviewing biological mechanisms of immunotherapy resistance in PDA.
• Outlining therapeutic combination strategies involving established and novel treatments.
• Exploring the interplay between epithelial, immune, and stromal compartments in PDA.

Key Points:

• Low neoantigen quality and quantity contribute to ICI resistance.
• Impaired T-cell infiltration and a dense, suppressive myeloid cell population exacerbate immunosuppression.
• Novel clinical investigations are evaluating combination therapies to enhance anti-tumor responses.

Conclusions:

• A comprehensive and personalized approach is required for successful treatment of PDA.
• Combination therapies targeting the immunosuppressive TME hold promise for improving ICI efficacy.
• Further research into novel therapeutic combinations is essential for advancing PDA treatment.